Simplify Launches Health Science ETF

Share post:

Simplify has just announced the launch of a new thematic ETF focused on the health industry. The Simplify Propel Opportunities ETF (SURI) is available for trade on the NYSE looking to offer exposure to companies with the health science industry that are overlooked by investors. SURI plans to do this through a multi-asset strategy giving at least 25% of its net assets to pharma, biotech, healthcare technologies, and life science companies. SURI will be sub-advised by Propel and will invest across market caps, countries, and currencies.

ETF Newz Says:

As of launch SURI’s top three holdings are, Plains All American Pipeline (22.11%), Athira Pharma Inc (7.16%), and the SPDR Bloomberg Barclays Investment Grade Floating Rate ETF (5.72%).

Related

Maintain Your Horses! A Space Bitcoin ETF May perhaps well also Already Be Priced into Crypto.

There is a growing belief that the recent price surge in bitcoin could already factor in the potential approval of a spot Bitcoin ETF- a pivotal strategic investment move that holds significant influence in the crypto market. Investors and financial enthusiasts alike are keenly awaiting regulatory approval, a decision that could potentially catalyze the future growth trajectory of bitcoin prices. This speculation underscores not only the potential value that bitcoin holds as a digital asset but also the evolving role of institutional reactiveness in the cryptocurrency landscape.

Tim Draper’s Bold Prediction: Bitcoin (BTC) Price Set to Skyrocket to $250K!

In the world of finance, Bitcoin is increasingly recognized as a transformative force. With the potential to challenge...

Bitcoin ETF: Navigating the Perils of SEC Rejection and Fierce Opposition from Funds

A recent court order has directed the Securities and Exchange Commission (SEC) to reconsider its denial of Grayscale's...

Nike’s Shocking 10% Plunge: Sales Outlook Slashed

Nike, a leading athletic apparel⁢ company, ⁣recently announced plans to reduce costs by $2 ‍billion over the next...